2019 Year in Review: Waldenström Macroglobulinemia

Oprozomib Found Active in Multiple Myeloma, Waldenström Macroglobulinemia

More work is needed to improve drug formulations for treatments for Waldenström macroglobulinemia.

Rituximab Maintenance Therapy in Waldenström Macroglobulinemia: Yay or Nay?

A considerable proportion of patients with Waldenström macroglobulinemia experience disease-related adverse events, such as hyperviscosity and neuropathy.

CXCR4 Mutations in Waldenström Macroglobulinemia as a Potential Therapeutic Target

Concurrent CXCR4 and MYD88 L265P mutations were found to occur in patients with Waldenström macroglobulinemia.

Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia

In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.

Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia

Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.

Single-Agent Ibrutinib Versus Rituximab-Based Chemoimmunotherapy in Waldenström Macroglobulinemia

No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.

Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement

According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.

CXCR4^S338X Clonality Predicts Ibrutinib Outcomes in Waldenström Macroglobulinemia

WM patients with high CXCR4S338X clonality had worse outcomes after ibrutinib therapy compared with patients who had low CXCR4S338X clonality.

Novel Therapies on the Horizon for Waldenström Macroglobulinemia

New treatments are in clinical development for Waldenström macroglobulinemia, a disease for which there is unmet clinical need.

Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia

A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.

Measuring Patient-Reported Outcomes in Waldenström Macroglobulinemia Patients Receiving Rituximab vs Ibrutinib-Rituximab

Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.

Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia

The model stratified patients into 3 risk groups based on median time to disease progression.